SIMPLE YET BRILLIANT

Veltio Pharma AB has recently been honored with the Bona Postulata-priset 2026, a recognition given to companies with strong growth potential. This award highlights the company’s commitment to improving pharmaceutical formulations through sustainable and practical technology. Being acknowledged alongside eight other remarkable companies based in Uppsala reflects the strength of Veltio Pharma’s vision and efforts in the pharmaceutical field. About the Bona Postulata-priset The

Veltio Pharma has taken an important step forward by joining the UIC Accelerate program at Uppsala Innovation Centre. This two-year accelerator will provide the company with tailored business coaching and strategic support to grow its nanotechnology-based oral formulation platform. This move aims to help Veltio Pharma bring more effective and sustainable therapies to the market. What UIC Accelerate Means for Veltio Pharma Being accepted into UIC Accelerate gives Veltio Pharma

Veltio Pharma AB recently closed a significant investment round, raising 8.5 million SEK. This capital injection marks a crucial step for the company. Expanding Research to Accelerate Drug Development With the new funding, Veltio Pharma plans to broaden its research activities. The investment will allow Veltio Pharma to: Increase the number of drug candidates under investigation Employ advanced technologies for formulation testing Collaborate with research institutions to v

Veltio Pharma has announced a significant leadership change with the appointment of Stina Lundgren as its new CEO. This move marks a new chapter for the company, promising fresh perspectives and renewed energy in its mission to advance pharmaceutical development. The decision reflects Veltio Pharma's commitment to growth and innovation in a competitive industry. Photo: Stina Lundgren. Who is Stina Lundgren? Stina Lundgren brings extensive experience in pharmaceutical leadersh